APTOF | tickerfilter.com

Fundamental analysis

32%

Profitability 35%

Dept financing 43%

Liquidity 18%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.85%

1 Month

1.36%

3 Months

4.76%

6 Months

37.75%

1 Year

-48.83%

2 Year

-48.83%

Key data

Stock price

$1.61

P/E Ratio

0.00

DAY RANGE

$1.61 - $1.61

EPS

-$7.38

52 WEEK RANGE

$0.64 - $4.00

52 WEEK CHANGE

-$48.83

MARKET CAP

2.986 M

YIELD

N/A

SHARES OUTSTANDING

2.552 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$7,024

AVERAGE 30 VOLUME

$7,513

Company detail

CEO: William G. Rice
Region: US
Website: aptose.com
Employees: 40
IPO year: 2006

Issue type:
Market: OTCM
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Aptose Biosciences discovers and develops personalized therapies addressing unmet medical needs in oncology. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and HR MDS. The company also develops luxeptinib, a dual bromodomain and extra-terminal domain motif motif motif protein and kinase inhibitor program.

APTOF - Aptose Biosciences Inc.